CD19 and neoplasm: While this may be clinically manageable in some cases, e.g., loss of healthy B cells with CARs directed against CD19, the adverse events due to on-target-off-tumor activity may be more severe with other targets, such as unwanted destruction of lung tissue after administration of anti-ERBB2(HER2)-CAR T cells designed to treat metastatic ERBB2+ cancer (15).